When was RayzeBio founded?

RayzeBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is RayzeBio located?

RayzeBio is headquartered in San Diego, United States.

How many employees does RayzeBio have?

As of Jul 31, 2026, the latest employee count at RayzeBio is 276.

Is RayzeBio a funded company?

RayzeBio is a funded company, having raised a total of $426M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 05, 2020.

How much is RayzeBio worth?

The last known valuation of RayzeBio was $***** as of Sep 11, 2023.

When was the latest funding round of RayzeBio?

RayzeBio's latest funding was a $***** Series D round on Aug 25, 2022, with participation from 7 investors.

Where does RayzeBio rank among its competitors?

RayzeBio ranks 241st amongst 2512 active competitors, of which 865 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of RayzeBio?

RayzeBio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

RayzeBio - 2026 Company Profile, Team, Funding & Competitors

RayzeBio is an acquired company based in San Diego (United States), founded in 2019 by Deborah Charych. It operates as a R&D company focused on manufacturing of cancer drugs. RayzeBio has raised $426M in funding from investors like Venrock, Sofinnova Investments and Versant Ventures, with last known valuation of $*****. The company has 2512 active competitors, including 865 funded and 622 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Website: rayzebio.com
Email ID: *****@rayzebio.com
Part Of

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Acquired

Total Funding

$426M in 4 rounds

Latest Funding Round

Series D, Aug 25, 2022, $*****

Last Known Valuation

$***** as on Sep 11, 2023

Investors

Venrock & 23 more

Ranked

241^st among 2512 active competitors

Employee Count

276 as on Jul 31, 2026

Investment & Acquisitions

RayzeBio

Similar Companies

Molecular Partners & 96 more

Exit Details

Acquired by Bristol-Myers Squibb (Dec 26, 2023)

View RayzeBio's full profile

RayzeBio got acquired by Bristol-Myers Squibb on Dec 26, 2023 at an acquisition amount of $*****.

Click here to take a look at RayzeBio's acquisition in detail

RayzeBio has raised a total funding of $426M over 4 rounds. Its first funding round was on Aug 05, 2020. Its latest funding round was a Series D round on Aug 25, 2022 for $*****. 7 investors participated in its latest round. RayzeBio has 24 institutional investors.

Here is the list of recent funding rounds of RayzeBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2022	8238747	Series D	3020774	1046453	7206051	3154610
Jun 08, 2021	8766932	Series C	5485612	8939893	7674922	Perceptive Advisors & 13 more
Nov 23, 2020	2113358	Series B	6068589	5853674	Venrock	Orbimed & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of RayzeBio's funding rounds and investors

The founders of RayzeBio is Deborah Charych.

Here are the details of RayzeBio's key team members:

Deborah Charych: Co-Founder & Chief Technology Officer of RayzeBio.

View details of RayzeBio's Founder profiles and Board Members

RayzeBio's employee count trend

RayzeBio has 276 employees as of Jul 26. Here is RayzeBio's employee count trend over the years:

Uncover RayzeBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RayzeBio include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of RayzeBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
241st	RayzeBio 2019, San Diego (United States), Acquired	R&D company focused on manufacturing of cancer drugs	$426M	Venrock, VenBio & 22 others	56/100